Clinical Trial Update: A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection [Phase 3]

View source ↗

Summary

Phase 3 trial comparing atezolizumab to observation as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma after surgery; study terminated with p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Urothelial Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Carcinoma, Transitional Cell | Phase 3 | Status: TERMINATED | Results posted: 2020-11-18